BioPharma Dive ٢١ مايو ٢٠٢٦ BioMarin notches win in study that could expand use of top-selling medicine
BioPharma Dive ٢٠ مايو ٢٠٢٦ After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets
BioPharma Dive ٢٠ مايو ٢٠٢٦ Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update